Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Allogeneic MSC

Cell therapy (Stem-cell derived) · developed by Longeveron

Phase 2 Most advanced trial (none active)
LGVN Developer
1 Registered trials

What is Allogeneic MSC?

Allogeneic MSC is an allogeneic bone marrow-derived mesenchymal stromal cell formulation. It is being studied in mild Alzheimer's disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Cell therapy (Stem-cell derived)
Therapy area
Neurology
Developer
Longeveron Inc. (LGVN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05233774 Phase 2 Mild Alzheimer's Disease Completed LGVN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Mild Alzheimer's Disease

More from Longeveron

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the LGVN page.

Follow LGVN, the company behind Allogeneic MSC

See LGVN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LGVN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.